In adult life, the type 2 isozyme of 11␤-hydroxysteroid dehydrogenase (11␤HSD2) protects the mineralocorticoid receptor (MR) from glucocorticoid by inactivating cortisol to cortisone. 11␤HSD2 activity has been reported in human fetal tissues, where glucocorticoids may impair fetal growth yet are also required for normal fetal development. Using digoxigenin-labeled complementary ribonucleic acid (RNA) probes and an in-house 11␤HSD2 antiserum, we have analyzed the expression of 11␤HSD2, MR, and glucocorticoid receptor (GR) in human fetal tissues of gestational age 6 -17 weeks (n ϭ 15). 11␤HSD2 expression was absent at gestational age 6ϩ weeks, but was expressed in abundance in many fetal tissues between 8 -12 weeks. At this time, 11␤HSD2 colocalized with GR messenger RNA (mRNA) expression in metanephros, gut, muscle, spinal cord and dorsal root ganglia, periderm, sex chords of testis, and adrenal. In particular within fetal kidney, intense expression of 11␤HSD2 and GR mRNA was observed over Bowman's capsule and the vascular tufts of developing glomeruli as they migrated from the surface of the kidney to the inner cortex. Only lung and adrenal medullary rests demonstrated high levels of GR mRNA but low levels of 11␤HSD2. 11␤HSD2 mRNA and immunoreactivity staining patterns were similar, with the exception of the fetal adrenal, where mRNA was localized to the outer definitive zone but immunoreactivity was localized to the inner fetal zone. Colocalization of 11␤HSD2 (and GR mRNA) with MR mRNA was observed principally within epithelial cells of collecting ducts, particularly after 16 weeks gestation when the pattern of distribution of 11␤HSD2 became more adult in nature. High levels of MR mRNA were observed within developing bone.
mRNA and immunoreactivity staining patterns were similar, with the exception of the fetal adrenal, where mRNA was localized to the outer definitive zone but immunoreactivity was localized to the inner fetal zone. Colocalization of 11␤HSD2 (and GR mRNA) with MR mRNA was observed principally within epithelial cells of collecting ducts, particularly after 16 weeks gestation when the pattern of distribution of 11␤HSD2 became more adult in nature. High levels of MR mRNA were observed within developing bone.
The data indicate that 11␤HSD2 in fetal life principally modulates ligand access to the GR in most fetal tissues, notably glomeruli and tubules in the developing kidney, testis, and periderm, and this may be have ramifications for fetal sodium homeostasis and differentiation. The development of tissues previously shown to have a critical requirement for glucocorticoids, such as lung and adrenal medulla, is facilitated by the expression of GR mRNA, but not 11␤HSD2. The expression of MR mRNA in high abundance in bone suggests a role for corticosteroids in human bone development, and the low/absent expression of 11␤HSD2 at this site suggests that it is functionally acting as a GR. (J Clin Endocrinol Metab 83: 4490 -4497, 1998) F UNCTIONALLY adrenal corticosteroids have been classified as being either glucocorticoid (cortisol, corticosterone) or mineralocorticoid (aldosterone) (1) . Glucocorticoids, through interaction with the glucocorticoid receptor (GR) exert a diverse array of physiological effects (antiinflammatory, stress response, sodium and water homeostasis, intermediary metabolism) (2) , whereas mineralocorticoids have a more defined role to stimulate epithelial sodium transport. In human adult life, the type 2 isozyme of 11␤-hydroxysteroid dehydrogenase (11␤HSD2) plays a crucial role in conferring specificity upon the mineralocorticoid receptor (MR). In vitro the MR has a similar affinity for cortisol and aldosterone (3, 4) ; 11␤HSD2 inactivates cortisol to cortisone in renal, colonic, salivary, and skin epithelial cells expressing the MR, ensuring that aldosterone occupies the receptor in vivo (5, 6) . Mutations in the gene encoding 11␤HSD2 explain a heritable form of human hypertension, the syndrome of apparent mineralocorticoid excess, in which cortisol acts a potent mineralocorticoid (7); a similar phenotype results when the enzyme is inhibited by the ingestion of licorice and its derivatives (8) .
11␤HSD2 is also expressed in human fetal tissues, including the placenta (9 -11) . Its function in these tissues is uncertain, although its expression in the placenta may serve to protect the developing fetus from the potentially deleterious effects of much higher concentrations of maternal glucocorticoids (12) . Glucocorticoid excess in utero has been proposed as an underlying mechanism explaining the epidemiological link between birth weight (and by inference fetal growth) and the subsequent development of hypertension in adult life (13, 14) . By contrast, certain tissues, for example lung and adrenal medulla, have a critical requirement for glucocorticoid during development (15) . Furthermore, at least in early fetal life before the full functional development of the kidney and gastrointestinal tract, tissues such as the placenta and skin may be responsible for regulating sodium homeostasis within the fetus.
Using complementary ribonucleic acid (cRNA) probes against the human MR, GR, and 11␤HSD2 and an in-house 11␤HSD2 antiserum, we have examined the expression of these ligands in human fetal tissues from gestational ages 6 -17 weeks.
Materials and Methods Tissue
Collection and processing of human fetal material were approved by the district and local hospital ethical committees and collected according to the Polkinghorne code of practice and full patient consent (16) . Fetal material was collected from elective surgical terminations of gestational age 6 -17 weeks (n ϭ 15 in total). For each window of gestational age studied (6ϩ, 8 -10, 12 , and 16 weeks), a minimum of three separate fetuses were studied. Determination of fetal age was defined by ultrasound measurements, crown to rump length, and heel to toe length measurements (17) . Material was treated with 50 mL heparin immediately posttermination to prevent blood clotting. Fetal and maternal tissues were separated through sterile sieves using sterile instruments. Fetal tissues were placed on ice, identified, and either snap-frozen or fixed in fresh 4% paraformaldehyde.
Synthesis of digoxigenin-labelled cRNA probes: 11␤HSD2, MR, and GR probes
Human 11␤HSD2, MR, and GR cRNA probes were synthesized from full-length human clones donated by Drs. Krozowski (18) , Arriza (4) , and Hollenberg (19) , respectively. Suitable fragments of the above clones were isolated by restriction digestion and subcloned into TA vector systems, 11␤HSD2 into PCR3.1 (Invitrogen, Leek, The Netherlands) and MR and GR into pGEM T (Promega Corp., Southampton, UK). For the human GR this was a 693-bp fragment encompassing nucleotides 808-1501 of the published complementary DNA, for MR this was a 450-bp fragment (nucleotides 2590 -3040 of the complementary DNA), and for 11␤HSD2 this was a 607-bp fragment (nucleotides 607-1497). The GR and MR probes shared less than 10% homology. Digoxigenin-UTP-labeled cRNA probes were synthesized by in vitro transcription using the appropriate restriction enzymes and SP6 T7 RNA polymerases (Boehringer Mannheim, Lewes, UK). Specifically, antisense cRNA probes for 11␤HSD2 were synthesized using T7 polymerase after linearization with ApaI; MR and GR antisense cRNA probes were synthesized using SP6 polymerase after linearization with ApaI. 11␤HSD2 sense cRNA probes were synthesized using SP6 polymerase after linearization with HindIII; for GR and MR, T7 polymerase was used after linearization with NotI. The nonradioactive digoxigenin RNA labeling and detection system (Boehringer Mannheim) allowed the detection of 0.1 g homologous RNA (20) .
In situ hybridization
Sagittal 5-m sections from the paraformaldehyde-fixed tissue blocks were mounted onto 3-amino propyl triethoxysilane-coated slides under ribonuclease-free conditions, dewaxed in serial dilutions of alcohol, and subjected to 30 min of 10 g proteinase K in 50 mmol/L Tris at 37 C. Sections were incubated with the 11␤HSD2, MR, and GR probes diluted in Hybrisol VI (Oncor Appligene, Hertfordshire, UK) overnight at 58, 42, and 45 C, respectively. The sections were subjected to a series of stringent posthybridization washes. Visualization of the probe was achieved by immunological colorimetric detection, with an alkaline phosphataseconjugated antidigoxigenin antibody (polyclonal, Fab from sheep) and 5-bromo-4-chloro-3-indolylphosphate/nitro-blue tetrazolium reaction.
Immunohistochemistry
Sagittal 5-m sections from the paraformaldehyde-fixed tissue blocks were mounted onto 10% poly-l-lysine-coated slides and dewaxed in serial dilutions of alcohol. Sections were treated with 30% hydrogen peroxide in methanol to block any endogenous peroxidase activity and were washed with 0.1 mol/L phosphate-buffered saline with 0.1% BSA. Slides were incubated with a 1:100 dilution of antibody derived against human 11␤HSD2 as previously reported (21) phosphate-buffered saline and BSA as before, and incubated with a 1:100 dilution of an antidonkey sheep horseradish peroxidase conjugate (The Binding Site, Birmingham, UK) for 30 min. Staining was visualized using diaminobenzidine, and sections were counterstained with hemotoxylin. In each immunocytochemical study, negative controls included tissues known to be devoid of 11␤HSD2 expression (e.g. human adult liver), sections in which the primary antiserum was omitted, and sections in which the primary antiserum was preadsorbed with the original immunizing peptide (21) .
Results
At the earliest gestational age studied (6ϩ weeks), there was minimal expression of MR and GR messenger RNA (mRNA) and low/absent expression of 11␤HSD2. MR mRNA expression was confined to the mesonephros (but not metanephros) and bone; GR mRNA expression was confined to the bone and epithelial cells of the gut ( Fig. 1 and Table 1 ).
Between fetal age 8 -12 weeks, 11␤HSD2 mRNA was readily detectable and was ubiquitously distributed. The same was true for MR and GR mRNA, although within any given tissue the localization of these ligands varied (Figs. 2 and 3) . Thus, in the kidney, 11␤HSD2 and GR expression was highest in the developing glomeruli, central collecting duct, and the epithelial cells of some renal tubules, both proximal and distal in origin (Figs. 2a and 3, c and d). In contrast, very little MR mRNA was present in extratubular sites. No hybridization was seen to control sense cRNA probes (Fig. 2b ). This pattern of distribution was most marked at fetal age 12 weeks. Here intense 11␤HSD2 and GR expression, but not MR mRNA, was observed over Bowman's capsule and the vascular tufts of developing glomeruli as they migrated from the surface of the kidney into the inner cortex. Expression of both 11␤HSD2 and the GR was markedly reduced in fully differentiated glomeruli (Fig. 3, c and  d ). 11␤HSD2 mRNA was also colocalized to MR mRNA within epithelial cells of renal collecting ducts (Fig. 3c) . By 16 weeks gestational age the renal expression of 11␤HSD2 had taken on a more adult pattern, with expression seen over collecting duct epithelial cells where it colocalized predominantly with MR mRNA (Fig. 4c ). 11␤HSD2 expression, however, together with GR mRNA was still observed over developing glomeruli in the outer cortex of the kidney.
At other sites, levels of GR mRNA were generally higher than MR mRNA between 8 -16 weeks gestation. Levels were notably high in muscle (Fig. 3b) and periderm (Fig. 3e) , gut, sex chords of the testis (Fig. 4, a and b) , and adrenal (Fig. 5) . One obvious exception was bone, where expression of 11␤HSD2 mRNA was low in contrast to the marked expression of MR mRNA (Figs. 1c and 3a) . MR mRNA was found in chondrocytes of developing ribs (Fig. 3b) and the perichondrial border, encompassing osteoblasts and chondrocytes in developing long bones (Fig. 3a) until 16 weeks gestation. After this gestational age the pattern of distribution of the MR was more adult in nature, with highest levels found in kidney, periderm, and colon where colocalization with 11␤HSD2 could be seen (Fig. 4, b and c) . Broadly speaking, within fetal tissues at this gestational age there was a close correlation between GR and 11␤HSD2 expression. Exceptions to this were the lung and possibly chromaffin tissue within the adrenal medulla, both of which had high levels of GR mRNA, but low levels of 11␤HSD2 (Figs. 4d and 5) . GR, MR, and 11␤HSD2 mRNA was present in neural tissue of the spinal cord and dorsal root ganglia (Fig. 3b) ) ; e, periderm (magnification, ϫ40). High levels of MR mRNA are seen in developing bone, neural tissues, and collecting duct epithlial cells. 11␤HSD2 and GR mRNA are observed to a lesser extent in bone, but in moderate/high amounts in neural tissues and adjacent muscle and periderm. Strong signal is seen in kidney in both tubular structures and glomeruli as they migrate from the surface of the cortex to the inner kidney (d). Expression is much less in fully differentiated glomeruli.
mRNA levels reflected protein expression, with intense 11␤HSD2 immunoreactivity observed in developing glomeruli and epithelial cells of collecting ducts, and some, but not all, proximal and distal renal tubules (Fig. 6, a, c , and e). Within the colon and periderm, 11␤HSD2 immunoreactivity was also evident in surface epithelial cells (Fig. 6, b and d) .
In the adrenal, however, 11␤HSD2 mRNA was found only in the outer definitive zone (Fig. 5) , whereas immunoreactivity was seen only in the inner fetal zone, excluding adrenal medullary rests (Fig. 6f) .
Discussion
11␤HSD is established as an important prereceptor signaling pathway in the analysis of corticosteroid hormone action (22) . The type 1 oxo-reductase enzyme is predominantly found in adult glucocorticoid target tissues, where it modulates glucocorticoid access to the GR (23, 24) . Expression of this isozyme cannot be demonstrated in human fetal life, at least at midgestation (11) . In contrast, 11␤HSD2 is found in adult mineralocorticoid tissues, kidney, colon, skin, and parotid, where it acts as a high affinity, NAD-dependent enzyme, efficiently inactivating cortisol to cortisone (18, 25) . Clinical observations of patients with deficiency of 11␤HSD2, for example children with the hypertensive syndrome apparent mineralocorticoid excess, or subjects consuming excessive quantities of licorice, in whom cortisol was shown to act as a potent mineralocorticoid, led to studies that confirmed that 11␤HSD2 protects the MR from cortisol excess. Thus, in vitro the MR has the same intrinsic affinity for cortisol and aldosterone; aldosterone occupies the MR in vivo only if cortisol is inactivated to cortisone by 11␤HSD2 at the site of the receptor (5-8). 11␤HSD activity has previously been documented in human fetal tissues, including the placenta, accounting for the low circulating cortisol/cortisone ratio in the fetal circulation compared to adulthood (1:1 vs. 8:1) (26, 27) . With the characterization and cloning of the two 11␤HSD isozymes, it became clear that the principal, if not exclusive, isozyme expressed in human placenta and fetal tissues was the NAD-dependent type 2 enzyme (10, 11, 18) . This coincided with renewed interest into the role of corti -FIG. 4 . Expression of 11␤HSD2, MR, and GR mRNA in fetal testis (a; magnification, ϫ10), intestine (b; magnification, ϫ10), kidney (c; magnification, ϫ4), and lung (d; magnification, ϫ25) at gestational age 16 weeks. GR and 11␤HSD2, but not MR, mRNA are localized to the sex chords of the testis. Expression of all three ligands is seen over epithelial cells of the gut and collecting ducts of the kidney, but expression of 11␤HSD2 and MR mRNA is highest. Some colocalization of GR and 11␤HSD2 is still observed over developing glomeruli. There is high expression of GR mRNA in all lung tissues, whereas 11␤HSD2 and MR mRNA are localized only weakly to bronchial columnar epithlial cells.
costeroids in fetal development with the suggestion that glucocorticoid-mediated programming in utero may explain the epidemiological link between fetal growth and adult diseases such as hypertension (12) (13) (14) . Earlier studies indicated that glucocorticoid excess in utero may impair neuronal development (28, 29) , may be teratogenic (30) , and may result in impaired fetal growth with reduced birth weight (31) . More recently, in some (32), but not all, rodent studies (33), inhibition of placental 11␤HSD2 across gestation was shown to result in hypertensive offspring with reduced birth weight. In humans the evidence for a relationship between placental 11␤HSD2 expression, glucocorticoids, and fetal growth is also conflicting (27, 34, 35) . Whatever the role of placental 11␤HSD2, this study demonstrates widespread expression of 11␤HSD2, GR, and MR mRNA between gestational age 8 -16 weeks at a time when fetal development is maximal. This implies that fetal tissues, if required, can protect themselves from maternal (or fetal) cortisol at an autocrine level, and it is perhaps naive therefore to expect any relationship between placental 11␤HSD2 expression per se and indexes of fetal growth.
Within individual fetal tissues, striking and temporal patterns of 11␤HSD2, MR, and GR mRNA expression were observed. Before 16 weeks gestational age, the expression of 11␤HSD2 mRNA was closely related to that of GR, notably in the glomeruli, periderm, sex chords of the testis, muscle, and adrenal, suggesting that 11␤HSD2 principally serves to regulate cortisol exposure to the GR at these sites. Before keratinization at 17-20 weeks gestation, the cells within the periderm contain microvilli and can transport urea, creatinine, and sodium (36) . This may represent an important mechanism by which the fetus maintains sodium and water balance before functional development of the kidneys and gastrointestinal tract, and our data suggest that this is predominantly glucocorticoid, rather than mineralocorticoid, regulated. Alternatively, glucocorticoids may play an im-FIG. 5. Expression of 11␤HSD2, MR, and GR mRNA in the fetal adrenal at gestational age 12 weeks. Magnification; a, ϫ10; b, ϫ4. Weak/absent expression of MR mRNA was seen over the gland. 11␤HSD2 mRNA was localized only to the outer definitive zone, whereas GR mRNA localization was more generalized.
FIG. 6. 11␤HSD2 immunoreactivity within human fetal kidney (a, c, and e), gut (b), periderm (d), and adrenal (f). At gestational ages 12-16 weeks, 11␤HSD2 protein is seen over proximal (c) distal, and collecting tubules in addition to glomeruli. Immunoreactivity is seen in surface epithelial cells of the gut and periderm. Within the adrenal, immunoreactivity is seen over the inner fetal zone, but not over the definitive zone or adrenal medullary rests. Magnification: a and e, ϫ4; b and c, ϫ40; d, ϫ100; f, ϫ10.
portant role in the differentiation and development of skin and other tissues expressing the GR; 11␤HSD2, in turn, may regulate this process.
This concept was illustrated best in the fetal kidney. At the earliest stage of development studied, the mesonephros, which may act as a functional kidney before the appearance of the metanephros, only expressed MR mRNA, suggesting that the receptor is unprotected at this stage. The metanephros develops from two components: the ureteric bud, which induces the mesenchymal blastema to form an epithelial condensation, which, in turn, induces dichotomous branching of the ureteric bud. The epithelial renal vesicle grows into an S-shaped convoluted tubule with a hookshaped Bowman's capsule, and the capillary tuft or glomerulus becomes linked to the vascular system. The ureteric bud gives rise to the renal pelvis, calices, and collecting ducts, whereas the S-shaped tubule differentiates into proximal and distal tubules. By 10 weeks gestation and thereafter, MR mRNA was only localized to structures derived from the ureteric bud, that is collecting ducts. In contrast, high levels of 11␤HSD2 were found in both components of the metanephros; proximal, distal, and collecting tubules; Bowman's capsule; and, most striking of all the developing glomeruli, where colocalization with GR mRNA was seen. This pattern of distribution is similar to that reported for vascular endothelial growth factor (VEGF), an important regulator of endothelial cell proliferation and migration (37) . Recombinantderived mice lacking the VEGF gene demonstrate abnormal nephron development, with glomeruli lacking capillary tufts (38) . VEGF is a glucocorticoid-dependent gene product, and it is interesting to speculate that the effects of glucocorticoids on renal development may be mediated through VEGF (39) . Renal function and morphology has not to our knowledge been reported in mice lacking the GR gene (15) .
Three other tissues warrant mention: lung, adrenal, and bone. Normal lung development is characterized by a glandular proliferation phase between 8 -19 weeks gestation during which there is gland-like duct growth with successive branching of ducts to form terminal sac-like canaliculi capable of forming alveoli. In the bronchial branches, columnar epithelium differentiates into ciliated epithelium. Intense GR mRNA expression was observed over all these structures from gestational age 8 -17 weeks in this study. In contrast, much lower levels of 11␤HSD2 and MR mRNA were seen only in bronchial columnar epithelial cells. Mice lacking the GR gene are known to have impaired development of the terminal bronchioles and alveoli (15) . Lung dysplasia was also observed in mice lacking CRF, and this could be reversed by prenatal glucocorticoid administration (40) . Glucocorticoids are known to regulate the production of the surfactant proteins SP-A, SP-B, SP-C, and SP-D (41, 42) and the apical sodium channel (43) , both of which may be important events in lung inflation at birth. Our findings of high levels of GR mRNA together with relatively low levels of 11␤HSD2 would facilitate high local concentrations of glucocorticoids, which are required for normal lung development.
The same principle may apply for the adrenal medulla. The adrenal originates from the coelemic epithelium between the gastric mesentery and mesonephros. From 8 weeks on, two distinct zones can be identified: an outer narrow progenitor layer, the neocortex or definitive zone, and an inner fetal zone. Neural crest-derived chromaffin cells invade the gland from gestational age 6 weeks on and differentiate by 8 weeks of age, but a morphological adrenal medulla is not formed until the neonatal period (44) . The huge relative size of the fetal adrenal compared to its adult counterpart can be explained predominantly by the large fetal zone that synthesizes dehydroepiandrosterone sulfate, the precursor for maternal estrogen throughout pregnancy. Because of a relative deficiency of 3␤-HSD in both zones of the fetal adrenal (45) , the adrenal would require progesterone for cortisol production. High levels of progesterone in the fetal circulation (46) together with the expression of both 17␣-and 21 hydroxylases in the fetal zone (47) suggest that cortisol is indeed synthesized by the fetal adrenal. The expression of 11␤HSD2 within the fetal adrenal is therefore puzzling. Firstly, this appears to be the only example reported to date where there exists a discrepancy between the sites of 11␤HSD2 synthesis and expression; 11␤HSD2 is transcribed in the outer progenitor layer, but is only expressed in the inner fetal zone. Secondly, it remains unclear as to why the fetal zone, if it is indeed synthesizing cortisol, would effectively inactivate it. Glucocorticoids are known to be an essential requirement for normal adrenal development, specifically the development of the adrenal chromaffin cells (15) and the expression of phenylethanolamine N-methyltransferase (48) . In keeping with these data, GR mRNA (but not MR mRNA) was ubiquitously distributed in both zones of the adrenal in addition to chromaffin cells scattered throughout the cortex. Chromaffin cells within the fetal zone did not express 11␤HSD2, which again would facilitate high glucocorticoid concentrations within these cells.
Finally, of some interest was the expression of high levels of MR in developing long bones and ribs. Expression appeared to be highest in osteoblasts, at bone-forming sites. Levels of GR and 11␤HSD2 mRNA were much lower, but they also appeared to be localized to osteoblasts. In adult bone, several studies have demonstrated the expression of functional GRs (49), and we have recently identified specific aldosterone binding in some rat osteoblastic cell lines (50) . The function of MR in developing bone, however, remains unknown.
Our data suggest therefore that corticosteroids will play a crucial role in the development and differentiation of many fetal tissues, and the expression of 11␤HSD2 may be a pivotal mechanism in this process. In particular, the expression of GR in developing glomeruli, testis, and skin may be of importance in normal renal and gonadal development and fetal sodium homeostasis; at these sites cortisol exposure to the GR is clearly modulated by 11␤HSD2 expression. In contrast, GR expression in the fetal lung and in adrenal chromaffin cells is not protected by 11␤HSD2. Similarly, at some sites (e.g. bone) and in early gestation (Ͻ8 weeks), the expression of MR and the absent expression of 11␤HSD2 suggest that the MR may be acting as a functional GR. By 16 weeks gestation a more adult pattern of expression of 11␤HSD2 and MR is observed, with colocalization in epithelial cells of the colon and collecting ducts.
